



Commercial/Healthcare Exchange PA Criteria Effective: June 2005

Prior Authorization: Sucraid

Products Affected: Sucraid (sacrosidase oral solution)

Medication Description: Sacrosidase is an oral enzyme produced as a by-product of the manufacture of baker's yeast (*Saccharomyces cerevisiae*). It is used for treating sucrase deficiency associated with congenital sucrase-isomaltase deficiency (CSID). CSID is a rare genetic disease in which the body lacks sucrase and isomaltase, enzymes necessary to break down and absorb sucrose and isomaltose, respectively.

Covered Uses: Congenital Sucrase-isomaltase deficiency

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Stool pH
3. Sucrose breath test
4. Small bowel biopsy

Age Restrictions: N/A

Prescriber Restrictions: Prescribed by, or in consultation with a gastroenterologist

Coverage Duration: 12 months

Other Criteria:

Approve Sucraid if the patient meets the following criteria:

- A) Patient has clinically documented Congenital sucrase-isomaltase deficiency (CSID) diagnosed by, or in consultation with a gastroenterologist; **AND**
- B) Patient has had a small bowel biopsy documenting >2 SD below mean for sucrase activity +/- isomaltase activity with normal lactase activity and normal villous architecture; **AND**
- C) Patient has positive stool pH (pH < 6.0); **AND**
- D) Patient has positive sucrose breath test (< 20 ppm H₂ over baseline)

References:

1. Product Information: Sucraid(R) oral solution, sacrosidase oral solution. QOL Medical, LLC (per DailyMed), Vero Beach, FL, 2014.

Last Res.5.14.2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	June, 2005
2	Annual Review	<p>CCI adopted EH template; Removed age restriction of 5 months of age and older</p> <p>CCI P&T Review History: 6/05, 12/05, 3/06, 6/06, 12/06, 6/07, 6/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 5/16, 5/17, 5/18, 5/19</p> <p>CCI Revision Record: 11/12, 2/16, 5/17, 5/18, 5/19, 11/19: Removed Aldurazyme, Fabrazyme, Kanuma – adopted EH Policies, renamed Policy Suclaird</p>	All	05/14/2020